De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

Nadia Harbeck,Oleg Gluz,Matthias Christgen,S. Kuemmel,Eva Maria Grischke,Michael Braun,Jochem Potenberg,Katja Krauss,Claudia Schumacher,Helmut Forstbauer,Toralf Reimer,Andrea Stefek,Hans Holger Fischer,E. Pelz,M. Graeser,Christine Eulenburg,Ronald E. Kates,Rachel Wuerstlein,Hans Kreipe,Ulrike Nitz

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

2021

503Background: Optimal use of de-escalated, particularly chemotherapy(CT)-free, neoadjuvant regimens in HER2+ early breast cancer (EBC) is currently unclear as there are limited survival data so fa...

Keywords:

Pertuzumab
early breast cancer
Medicine
Chemotherapy
Oncology
survival data
Internal medicine
Biomarker (medicine)
Paclitaxel
Trastuzumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations